Abstract:Breast cancer (BC) is the most common non-skin cancer and the second leading cause of cancer death in American women. The initiation and progression of BC can proceed through the accumulation of genetic and epigenetic changes that allow transformed cells to escape the normal cell cycle checkpoint control. Unlike nucleotide mutations, epigenetic changes such as DNA methylation, histone posttranslational modifications (PTMs), nucleosome remodeling and non-coding RNAs are generally reversible and therefore potentially responsive to pharmacological intervention. Epigenetic dysregulations are critical mechanisms for impaired antitumor immunity, evasion of immune surveillance, and resistance to immunotherapy. Compared to highly immunogenic tumor types, such as melanoma or lung cancer, breast cancer has been viewed as an immunologically quiescent tumor which displays a relatively low population of tumor-infiltrating lymphocytes (TIL), low tumor mutational burden (TMB) and modest response rates to immune checkpoint inhibitors (ICI). Emerging evidence suggests that agents targeting aberrant epigenetic modifiers may augment host antitumor immunity in BC via several interrelated mechanisms such as enhancing tumor antigen presentation, activation of cytotoxic T cells, inhibition of immunosuppressive cells, boosting response to ICI, and induction of immunogenic cell death (ICD). These discoveries have established a highly promising basis for using combinatorial approaches of epigenetic drugs with immunotherapy as an innovative paradigm to improve outcomes of BC patients. In this review, we summarize the current understanding of how epigenetic processes regulate immune cell function and antitumor immunogenicity in the context of the breast tumor microenvironment. Moreover, we discuss the therapeutic potential and latest clinical trials of the combination of immune checkpoint blockers with epigenetic agents in breast cancer.

Epigenetic therapy combined with immunotherapy: a novel strategy for cancer therapy

Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors

A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy

Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy

Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance

Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model

H3K4 trimethylation regulates cancer immunity: a promising therapeutic target in combination with immunotherapy

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication

Epigenetics and immunotherapy in colorectal cancer: progress and promise

Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy

Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy

Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications

Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints

[Immune-checkpoints: the new anti-cancer immunotherapies]

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy